ProKidney Corp. Class A PROK 深 滬
已收盤 02-06 16:00:00 美东时间
1.87
+0.140
+8.09%
華盛通- 最 高1.885
- 今 開1.74
- 成交量 94.63万股
- 最 低 1.74
- 昨 收 1.73
- 總市值 5.63亿
- 52周最高 7.13
- 市盈率 靜 --
- 換手率 0.31%
- 52周最低 0.4603
- 委 比 84.40%
- 總股本 3.01亿
- 歷史最高 14.19
- 量 比 0.68
- 振 幅 8.38%
- 歷史最低 0.4603
- 每 手 1
- 風險率 0.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ProKidney Advances Rilparencel Program and Manufacturing Expansion
An announcement from ProKidney ( ($PROK) ) is now available. ProKidney has upda...
01-12 21:49
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
ProKidney Corp.'s CEO, Bruce Culleton, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company's lead product, rilparencel, is in a Phase 3 study for chronic kidney disease and Type 2 diabetes. A live webcast and 30-day replay will be available on ProKidney's website.
01-06 12:30
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection poi...
2025-12-17 00:53
HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on ProKidney (NASDAQ:PROK) with a Buy rating and announces Price Target of $12.
2025-12-16 20:03
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the
2025-11-11 05:36
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
A Phase 2 REGEN-007 trial demonstrated that rilparencel, a cell therapy, significantly slowed chronic kidney disease (CKD) progression in diabetic patients. Group 1 showed a 78% improvement in eGFR slope, with no serious adverse events. Phase 3 PROACT 1, which uses eGFR slope as a surrogate endpoint, has enrolled over half its required participants, with topline results expected in Q2 2027. Rilparencel is the first cell therapy in a Phase 3 trial...
2025-11-06 16:00
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
ProKidney Corp. will present two posters at the American Society of Nephrology's Kidney Week 2025 in Houston, TX, on November 6-9: one on the Phase 2 REGEN-007 study results for renal autologous cell therapy in diabetes and CKD, and another on the inflammatory profile of rilparencel. The posters will be available on the company’s website post-event. ProKidney focuses on developing cellular therapies for chronic kidney disease, with its lead candi...
2025-10-20 11:30
ProKidney Sells Greensboro Property for $19.1 Million
ProKidney ( ($PROK) ) has issued an update. ProKidney Corp. announced that on O...
2025-10-18 05:00
ProKidney Corp. Signs New $19.1M Agreement To Sell Greensboro, NC Property After Prior Deal Termination
As previously disclosed, on May 8, 2025, ProKidney Corp. (the "Company"), through its wholly owned subsidiary, ProKidney Acquisition Company, LLC ("Acquisition Sub"), entered into a purchase and sale agreement with
2025-10-18 04:41
